FABP5 and type 2 diabetes mellitus: As identification of small molecule inhibitors of FABP has been proven to be effective in treating atherosclerosis and type II diabetes in mouse models [14], we initially intended to screen small molecules that might specifically bind to the lipid-binding pocket of E-FABP using computational docking analysis [15].